What Are Sorptive and Reactive Packaging Materials?

Sorptive packaging materials absorb or adsorb drug product constituents such as preservatives, flavors, or even the API itself. Reactive packaging materials can chemically alter the drug product, leading to degradation or instability.

Both types pose significant risks during long-term storage and must be carefully considered during container closure selection and validation.

Examples of Sorptive Packaging Materials

• HDPE Bottles: May adsorb lipophilic drugs or volatile components due to hydrophobic surfaces
• Rubber Closures: Can bind preservatives like benzyl alcohol or methylparaben
• Desiccant Pouches: Can reduce moisture below intended equilibrium, causing API degradation
• Silicone Oil (lubricant): Found in syringes; may interact with protein-based biologics

Understanding these interactions is essential for conducting meaningful stability studies and ensuring accurate data.

Examples of Reactive Packaging Materials

• Glass (Type II or III): Leaching of alkali ions may alter pH of aqueous drugs
• PVC Blisters: May release residual monomers or plasticizers under heat
• Natural Rubber: High extractables and potential for oxidative reactions
• Aluminum Foil: Can react with acidic or basic formulations in direct contact

Reactive materials often require surface coatings or barrier layers to reduce direct drug contact.

Mechanisms of Packaging-Drug Interactions

Common mechanisms include:

• Adsorption: APIs or excipients adhere to packaging surfaces
• Absorption: Volatile compounds penetrate polymer matrix
• Leaching: Packaging additives migrate into the drug product
• pH Shift: Interaction with glass or closures changes formulation pH

These interactions may lead to potency loss, increased impurities, or alteration of physicochemical properties.

Case Study: Loss of Preservative Due to Rubber Stopper

A multidose injectable formulation lost over 30% of its preservative within 3 months at 25°C due to sorption by the rubber stopper. Subsequent microbial testing failed USP preservative effectiveness test, prompting reformulation and change to fluoropolymer-coated stoppers.

Testing and Risk Evaluation Protocols

• ✓ Conduct extractables and leachables studies using ICH and GMP guidelines
• ✓ Assess pH shift, preservative loss, and assay variation over time
• ✓ Validate analytical methods for detecting trace impurities
• ✓ Perform surface area to volume ratio analysis for sorptive packaging
• ✓ Use simulation studies under accelerated conditions (40°C/75% RH)

Regulatory Requirements and Expectations

Regulatory agencies such as the EMA and USFDA expect that packaging components used in stability studies are fully qualified and validated for the intended drug product. According to ICH Q1A(R2):

• ✔ Stability studies must use the same packaging configuration as commercial product
• ✔ Interaction studies must be provided in Module 3.2.P.2 and 3.2.P.7 of the CTD
• ✔ Container closure integrity (CCI) must be demonstrated

Neglecting sorptive or reactive risks can lead to deficiencies during dossier review or post-market recalls.

Mitigation Strategies

• Use coated stoppers (e.g., Teflon) or inert films (e.g., PVDC) to reduce interaction
• Employ non-leaching ink and adhesives in labels and cartons
• Switch from natural to bromobutyl or chlorobutyl rubber closures
• Choose Type I glass or cyclic olefin polymer containers for aqueous biologics
• Add antioxidant stabilizers for oxidation-prone formulations in plastic containers

Sample Stability Study Comparison Table

Checklist for Packaging Component Evaluation

• ☑ Identify material composition of all contact components
• ☑ Perform E&L studies for all packaging systems
• ☑ Test for interaction during long-term and accelerated stability
• ☑ Compare assay, impurities, and other critical parameters
• ☑ Justify packaging selection in CTD submission

Conclusion

Sorptive and reactive packaging materials can compromise drug stability, safety, and regulatory compliance. By proactively identifying and testing these interactions, pharma companies can avoid stability failures, reduce development delays, and improve product quality. A science-based approach to packaging evaluation is essential for any robust stability program.

References:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs
• USP , , , ,
• EMA Guideline on Plastic Immediate Packaging Materials
• WHO Stability Testing Guidelines – Technical Report Series